

# Sample Company

## 2nd Quarter Review

Jan 2015 through Jun 2015 vs. Jan 2016 through Jun 2016

	Jan '15 - Jun '15	Jan '16 - Jun '16	Difference	% Difference	Excellus Benchmark	Difference	% Difference
<b>Enrollment</b>							
Average Contracts	554	559	5	0.9%			
Average Members	1,251	1,251	0	0.0%			
Average Members/Contract	2.26	2.24	-0.02	-0.9%			
<b>Costs by Service Category</b>							
Inpatient	\$430,884	\$537,125	\$106,240	24.7%			
Outpatient	\$350,906	\$314,852	-\$36,054	-10.3%			
Physician	\$485,007	\$447,528	-\$37,479	-7.7%			
Other	\$48,547	\$65,916	\$17,369	35.8%			
Pharmacy	\$408,825	\$434,543	\$25,718	6.3%			
<b>Total Costs</b>	<b>\$1,724,170</b>	<b>\$1,799,965</b>	<b>\$75,795</b>	<b>4.4%</b>			
<b>PMPM Cost</b>							
Inpatient	\$57.39	\$71.56	\$14.17	24.7%	<b>\$64.85</b>	\$6.71	10.3%
Outpatient	\$46.74	\$41.95	-\$4.79	-10.3%	<b>\$86.41</b>	-\$44.46	-51.5%
Physician	\$64.60	\$59.62	-\$4.98	-7.7%	<b>\$97.36</b>	-\$37.74	-38.8%
Other	\$6.47	\$8.78	\$2.32	35.8%	<b>\$9.86</b>	-\$1.08	-10.9%
Pharmacy	\$54.45	\$57.89	\$3.44	6.3%	<b>\$42.94</b>	\$14.95	34.8%
<b>Total Medical</b>	<b>\$229.64</b>	<b>\$239.80</b>	<b>\$10.16</b>	<b>4.4%</b>	<b>\$301.42</b>	<b>-\$61.62</b>	<b>-20.4%</b>
<b>Paid/Service</b>							
Inpatient	\$13,057.10	\$14,920.13	\$1,863.03	14.3%			
Outpatient	\$223.22	\$202.09	-\$21.14	-9.5%			
Physician	\$81.06	\$73.78	-\$7.29	-9.0%			
<b>Utilization Services per 1000</b>							
Inpatient	52.7	57.6	4.8	9.1%	<b>68.0</b>	-10.45	-15.4%
Outpatient	2512.5	2490.8	-21.7	-0.9%	<b>2,021.0</b>	469.81	23.2%
Physician	9562.6	9697.8	135.2	1.4%	<b>8,560.0</b>	1,137.84	13.3%
<b>Total Medical</b>	<b>12,127.9</b>	<b>12,246.2</b>	<b>118.3</b>	<b>1.0%</b>	<b>10,649.0</b>	<b>1,597.20</b>	<b>15.0%</b>
<b>High Claims Overview (&gt;\$25,000)</b>							
High Claims	9	12	3	33.3%			
High Claim Costs	\$466,131	\$677,803	\$211,672	45.4%			
Average Costs per Claim	\$51,792	\$56,484	\$4,691	9.1%			
% of Total Costs	27.0%	37.7%	-	10.6%	<b>25%</b>	-	12.7%
<b>Pharmacy</b>							
PMPM Plan Costs	\$54.45	\$57.89	\$3.44	6.3%	<b>\$42.94</b>	\$14.95	34.8%
Prescriptions/1000	12,772.0	12,745.0	-26.97	-0.2%	<b>10,062.0</b>	2,683.0	26.7%
Plan Cost per Prescription	\$51.16	\$54.51	\$3.35	6.5%			
Member Cost per Prescription	\$18.66	\$19.73	\$1.08	5.8%			
Generic Utilization	88.5%	88.7%	-	0.2%	<b>80.0%</b>	-	8.7%



# Sample Company

2nd Quarter Review  
High Cost Claimant Analysis

Jan 2016 through Jun 2016

	Claimant	Most Costly Diagnosis	Current Plan Cost	UM	CM	DM	RX Sp CM	Current Status	Next 12 Months Forecast > \$50K
1	000001330148	M41 Scoliosis	\$209,182	YES	NA	NA	NA	Active	NO
2	000001900662	E24 Cushing's syndrome	\$98,257	YES	YES	YES	NA	Active	YES
3	000000564412	Rx - Cancer - Imbruvica	\$61,020	YES	YES	YES	YES	Active	YES
4	000000489213	T82 Complications of cardiac and vascular prosthetic device	\$58,494	YES	NA	YES	NA	Active	YES
5	000000068216	Rx - Multiple Sclerosis - Betaseron	\$35,205	YES	NA	NA	YES	Active	YES
6	000000156100	J96 Respiratory failure, not elsewhere classified	\$34,448	YES	NA	YES	NA	Active	NO
7	000001517108	A41 Other sepsis	\$33,182	YES	NA	YES	NA	Active	NO
8	000011870737	R73 Elevated blood glucose level	\$32,948	YES	NA	YES	YES	Active	YES
9	000002405805	I25 Chronic ischemic heart disease	\$32,104	YES	YES	YES	NA	Active	NO
10	000000500070	I25 Chronic ischemic heart disease	\$30,742	YES	NA	NA	NA	Active	NO
11	000001539216	Rx - Rheumatic Disease - Humira Pen	\$26,383	YES	YES	NA	YES	Active	YES
12	000000081324	M16 Osteoarthritis of hip	\$25,838	YES	NA	YES	NA	Active	NO
<b>Total</b>			<b>\$677,803</b>						

UM - Utilization Management, CM - Case Management, DM - Disease Management, Rx Sp CM - Pharmacy Benefit Specialty Drug CM

Jan 2015 through Jun 2015

	Claimant	Most Costly Diagnosis	Current Plan Cost	UM	CM	DM
1	000010841157	403 Hypertensive Renal Disease	\$127,879	YES	NA	NA
2	000000417962	737 Curvature of Spine	\$94,215	YES	NA	NA
3	000000564412	Rx - Cancer - Imbruvica	\$51,948	YES	YES	YES
4	000000489213	585 Chronic Renal Failure	\$42,194	YES	NA	YES
5	000001255721	738 Other Acquired Musculoskeletal Deformity	\$35,207	YES	NA	NA
6	000000068216	Rx - Multiple Sclerosis - Betaseron	\$31,222	YES	NA	NA
7	000001539216	Rx - Rheumatic Disease - Humira Pen	\$28,855	YES	YES	NA
8	000002132064	715 Osteoarthritis and Allied Disorders	\$28,308	YES	NA	YES
9	000001255588	730 Osteomyelitis, Periostitis, and Other Infections Involv	\$26,303	YES	NA	NA
<b>Total</b>			<b>\$466,131</b>			

UM - Utilization Management, CM - Case Management, DM - Disease Management



# Sample Company

## 2nd Quarter Review

### Top 20 Paid & Top 20 Dispensed Drugs

#### Top 20 Paid

Drug Name	Therapeutic Class	Jan '16 - Jun '16			Jan '15 - Jun '15		
		Plan Cost	Scripts	Cost/Script	Plan Cost	Scripts	Cost/Script
1. IMBRUVICA	Antineoplastic Agent	\$58,076	6	\$9,679.38	\$43,665	5	\$8,733.02
2. HUMIRA PEN	Analgesic, Anti-inflammatory or Antipyretic	\$50,943	15	\$3,396.21	\$40,939	15	\$2,729.24
3. BETASERON	Multiple Sclerosis Agents	\$26,459	5	\$5,291.83	\$23,545	5	\$4,708.95
4. ENBREL SURECLICK	Analgesic, Anti-inflammatory or Antipyretic	\$22,835	7	\$3,262.11	\$0	0	\$0.00
5. TECFIDERA	Multiple Sclerosis Agents	\$21,552	4	\$5,387.95	\$20,889	4	\$5,222.20
6. CREON	Gastrointestinal Therapy Agents	\$13,180	4	\$3,295.00	\$560	1	\$560.11
7. Subject to protected health.	Subject to protected health.	\$10,878	22	\$494.45	\$14,231	35	\$406.59
8. HUMIRA	Analgesic, Anti-inflammatory or Antipyretic	\$10,752	3	\$3,583.84	\$0	0	\$0.00
9. BENLYSTA	Immunological Agent	\$10,680	4	\$2,670.06	\$19,789	6	\$3,298.13
10. NOVOLOG FLEXPEN	Endocrine	\$10,415	8	\$1,301.87	\$10,770	8	\$1,346.24
11. REMICADE	Analgesic, Anti-inflammatory or Antipyretic	\$10,214	3	\$3,404.71	\$0	0	\$0.00
12. Subject to protected health.	Subject to protected health.	\$8,259	6	\$1,376.58	\$14,497	13	\$1,115.15
13. CELLCEPT	Immunosuppressive Agents	\$7,240	5	\$1,448.00	\$0	0	\$0.00
14. ENBREL	Analgesic, Anti-inflammatory or Antipyretic	\$6,928	2	\$3,464.24	\$31,669	11	\$2,878.96
15. HUMALOG	Endocrine	\$6,893	18	\$382.96	\$2,826	13	\$217.36
16. VICTOZA	Endocrine	\$6,237	6	\$1,039.48	\$6,091	8	\$761.42
17. LANTUS SOLOSTAR	Endocrine	\$5,723	20	\$286.15	\$7,104	20	\$355.21
18. JANUVIA	Endocrine	\$4,956	12	\$412.96	\$1,618	6	\$269.63
19. HUMALOG KWIKPEN	Endocrine	\$4,926	4	\$1,231.42	\$5,167	6	\$861.25
20. ASACOL HD	Gastrointestinal Therapy Agents	\$4,852	4	\$1,212.93	\$493	2	\$246.72
<b>Top 20 Total:</b>		<b>\$301,998</b>	<b>158</b>		<b>\$243,852</b>	<b>158</b>	
<b>All Other Total:</b>		<b>\$132,545</b>	<b>7814</b>		<b>\$164,973</b>	<b>7833</b>	
<b>Pharmacy Total:</b>		<b>\$434,543</b>	<b>7972</b>		<b>\$408,825</b>	<b>7991</b>	
<b>Top 20 % of Total:</b>		<b>69.5%</b>	<b>2.0%</b>		<b>59.6%</b>	<b>2.0%</b>	

#### Top 20 Utilized

Drug Name	Therapeutic Class	Jan '16 - Jun '16			Jan '15 - Jun '15		
		Plan Cost	Scripts	Cost/Script	Plan Cost	Scripts	Cost/Script
1. Subject to protected health.	Subject to protected health.	\$2,845	391	\$7.28	\$2,071	409	\$5.06
2. LEVOTHYROXINE SODIUM	Endocrine	\$920	218	\$4.22	\$1,323	217	\$6.10
3. OMEPRAZOLE	Gastrointestinal Therapy Agents	\$59	160	\$0.37	\$190	168	\$1.13
4. ATORVASTATIN CALCIUM	Cardiovascular Therapy Agents	\$213	153	\$1.39	\$335	160	\$2.09
5. LISINAPRIL	Cardiovascular Therapy Agents	\$36	150	\$0.24	\$40	146	\$0.27
6. Subject to protected health.	Subject to protected health.	\$131	99	\$1.33	\$55	91	\$0.61
7. AMOXICILLIN	Anti-Infective Agents	\$127	95	\$1.34	\$267	117	\$2.29
8. HYDROCHLOROTHIAZIDE	Cardiovascular Therapy Agents	\$2	94	\$0.03	\$9	84	\$0.10
9. FLUTICASONE PROPIONATE	Respiratory Therapy Agents	\$54	93	\$0.58	\$225	98	\$2.30
10. AZITHROMYCIN	Anti-Infective Agents	\$52	90	\$0.58	\$378	85	\$4.45
11. GABAPENTIN	Central Nervous System Agents	\$514	70	\$7.34	\$1,428	50	\$28.55
12. MONTELUKAST SODIUM	Respiratory Therapy Agents	\$191	69	\$2.77	\$269	69	\$3.90
13. SIMVASTATIN	Cardiovascular Therapy Agents	\$318	64	\$4.97	\$0	87	\$0.00
14. HYDROCODONE/ACETAMINOPHEN	Analgesic, Anti-inflammatory or Antipyretic	\$253	62	\$4.08	\$527	77	\$6.84
15. PREDNISONE	Endocrine	\$77	61	\$1.25	\$181	67	\$2.71
16. METFORMIN HCL	Endocrine	\$72	60	\$1.21	\$10	59	\$0.16
17. CYCLOBENZAPRINE HCL	Locomotor System	\$54	53	\$1.02	\$23	60	\$0.39
18. AMLODIPINE BESYLATE	Cardiovascular Therapy Agents	\$8	53	\$0.14	\$6	81	\$0.08
19. PANTOPRAZOLE SODIUM	Gastrointestinal Therapy Agents	\$59	52	\$1.13	\$38	26	\$1.46
20. VALACYCLOVIR HCL	Anti-Infective Agents	\$415	51	\$8.15	\$313	35	\$8.94
<b>Top 20 Total:</b>		<b>\$6,402</b>	<b>2138</b>		<b>\$7,689</b>	<b>2186</b>	
<b>All Other Total:</b>		<b>\$428,141</b>	<b>5834</b>		<b>\$401,137</b>	<b>5805</b>	
<b>Pharmacy Total:</b>		<b>\$434,543</b>	<b>7972</b>		<b>\$408,825</b>	<b>7991</b>	
<b>Top 20 % of Total:</b>		<b>1.5%</b>	<b>26.8%</b>		<b>1.9%</b>	<b>27.4%</b>	

